Equities

Halozyme Therapeutics Inc

Halozyme Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)60.98
  • Today's Change1.33 / 2.23%
  • Shares traded1.12m
  • 1 Year change+65.93%
  • Beta1.2922
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform6
Hold5
Sell0
Strong Sell0

Share price forecast in USD

The 10 analysts offering 12 month price targets for Halozyme Therapeutics, Inc. have a median target of 63.00, with a high estimate of 75.00 and a low estimate of 50.00. The median estimate represents a 3.31% increase from the last price of 60.98.
High23.0%75.00
Med3.3%63.00
Low-18.0%50.00

Dividends

Dividend information is not available for Halozyme Therapeutics Inc.
Div growth (TTM)--
More ▼

Earnings history & estimates in USD

On Oct 31, 2024, Halozyme Therapeutics, Inc. reported 3rd quarter 2024 earnings of 1.27 per share. This result exceeded the 0.98 consensus of the 8 analysts covering the company and exceeded last year's 3rd quarter results by 69.33%.
The next earnings announcement is expected on Feb 18, 2025.
Average growth rate+15.11%
Halozyme Therapeutics, Inc. reported annual 2023 earnings of 2.77 per share on Feb 20, 2024.
Average growth rate+51.87%
More ▼

Revenue history & estimates in USD

Halozyme Therapeutics, Inc. had 3rd quarter 2024 revenues of 290.08m. This bettered the 251.06m consensus of the 9 analysts covering the company. This was 78.91% above the prior year's 3rd quarter results.
Average growth rate+8.78%
Halozyme Therapeutics, Inc. had revenues for the full year 2023 of 829.25m. This was 25.62% above the prior year's results.
Average growth rate+44.18%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.